Subscribe
Sign in
Home
Podcast
Archive
Leaderboard
About
1:09:43
🎧 The GLP-1 business model problem, Ep. 1 with Prof. Alex Miras
Why the drug does the heavy lifting, price trumps everything, and muscle loss might not be what we think
Feb 15
Â
•
Â
Ashwin Sharma, MD
8
1
2
Latest
Top
Discussions
GLP-1s go to the Super Bowl
Ro bets big, Novo's oral Wegovy finally arrives, and Hims crosses a line with the FDA
Feb 8
Â
•
Â
Ashwin Sharma, MD
12
1
Consumer health apps are dead
Long live the agents
Jan 11
Â
•
Â
Ashwin Sharma, MD
29
3
The 5 most important ideas for 2026
Seismic shifts are underway in the GLP-1 market
Dec 29, 2025
Â
•
Â
Ashwin Sharma, MD
27
3
Is Your Telehealth Platform Scaring Patients Away?
Design is the overlooked moat in digital health
Dec 16, 2025
Â
•
Â
Ashwin Sharma, MD
5
When Science Fails, and Startups Fly
Novo has cause to be disheartened, while Function Health and GLP-1 consumers in India do not
Nov 25, 2025
Â
•
Â
Ashwin Sharma, MD
19
2
Trump's announcement shifts competition in the GLP-1 market
Who will benefit, and who won’t?
Nov 11, 2025
Â
•
Â
Ashwin Sharma, MD
18
1
3
Why Can't Anyone Stop Compounded GLP-1s?
Because federal, legal, and private forces won't allow it
Nov 2, 2025
Â
•
Â
Ashwin Sharma, MD
25
3
6
See all
GLP-1 Digest
The GLP-1 newsletter for founders, operators and investors.
Subscribe
Recommendations
The Argument
Jerusalem Demsas
The Gut Group
Dr Arif Hussenbux MBBS
Big Pharma Sharma
Big Pharma Sharma
In-Network
David Ohta
GLP-1 Digest
Subscribe
About
Archive
Recommendations
Sitemap
This site requires JavaScript to run correctly. Please
turn on JavaScript
or unblock scripts